Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Letter to the Editor
  • Published:

No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients

Leukemia volume 23, pages 1008–1009 (2009)Cite this article

Myeloproliferative neoplasms (MPNs) have been associated with high incidence of thrombosis and bleeding episodes, which significantly contribute to disease-related morbidity and mortality.1 Notably, clinical data indicate an association of the JAK2 V617F mutation, seen in nearly all polycythemia vera cases and half of those with essential thrombocythemia with erythrocytosis, leukocytosis and thrombotic complications. Particularly for essential thrombocythemia, a recent overview has suggested that the JAK2 V617F positivity may be associated with an increased risk of thrombosis, an effect mediated by the leukocytosis conferred by the mutation.2 Several studies have indicated that a substantial proportion of patients with idiopathic Budd–Chiari syndrome, portal vein or mesenteric vein thrombosis carry the JAK2 V617F mutation, even in the absence of overt clinical or hematological features of an MPN.3 Detection of JAK2 V617F mutation in this setting is a marker of a ‘latent’ MPN as positive patients appear to have bone marrow histological features characteristic of MPN.3, 4

Recently, Mercier et al. screened 27 patients aged <40 years, who had experienced an acute myocardial infarction (AMI). Three out of 27 (11.1%) patients carried the JAK2 V617F mutation, leading the authors to conclude that a latent MPN may often be present in this group of patients, warranting screening for the V617F mutation.5 In contrast, in a study of 28 patients with AMI at a young age (defined as <50 years), none was found to harbour the JAK2 V617F mutation. That group of patients was part of a larger cohort of patients with arterial or venous thrombosis outside the splanchnic circulation. The study suggested that screening for JAK2 V617F mutation is not warranted as part of the hypercoagulable work-up in patients with non-splanchnic thrombosis.6

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Elliott MA, Tefferi A . Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275–290.

    Article  CAS  Google Scholar 

  2. Dahabreh IJ, Zoi K, Giannouli S, Zoi C, Loukopoulos D, Voulgarelis M . Is JAK2 V617F mutation more than a diagnostic index? A meta-analysis of clinical outcomes in essential thrombocythemia. Leuk Res 2009; 33: 67–73.

    Article  CAS  Google Scholar 

  3. Boissinot M, Lippert E, Girodon F, Dobo I, Fouassier M, Masliah C et al. Latent myeloproliferative disorder revealed by the JAK2-V617F mutation and endogenous megakaryocytic colonies in patients with splanchnic vein thrombosis. Blood 2006; 108: 3223–3224.

    Article  CAS  Google Scholar 

  4. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 2008; 111: 4922–4929.

    Article  CAS  Google Scholar 

  5. Mercier E, Cochery-Nouvellon E, Lavigne G, Bertinchant JP, Gris JC . In support of the revised World Health Organization diagnostic criteria for essential thrombocythemia: JAK2 V617F and premature myocardial infarction. J Thromb Haemost 2008; 6: 206–207.

    Article  CAS  Google Scholar 

  6. Pardanani A, Lasho TL, Hussein K, Schwager SM, Finke CM, Pruthi RK et al. JAK2V617F mutation screening as part of the hypercoagulable work-up in the absence of splanchnic venous thrombosis or overt myeloproliferative neoplasm: assessment of value in a series of 664 consecutive patients. Mayo Clin Proc 2008; 83: 457–459.

    Article  Google Scholar 

  7. Jones AV, Kreil S, Zoi K, Waghorn K, Curtis C, Zhang L et al. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood 2005; 106: 2162–2168.

    Article  CAS  Google Scholar 

  8. Newcombe RG . Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17: 857–872.

    Article  CAS  Google Scholar 

  9. Remacha AF, Estivill C, Sarda MP, Mateo J, Souto JC, Canals C et al. The V617F mutation of JAK2 is very uncommon in patients with thrombosis. Haematologica 2007; 92: 285–286.

    Article  Google Scholar 

  10. Pardanani A, Lasho TL, Schwager S, Finke C, Hussein K, Pruthi RK et al. JAK2V617F prevalence and allele burden in non-splanchnic venous thrombosis in the absence of overt myeloproliferative disorder. Leukemia 2007; 21: 1828–1829.

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported by the grant PENED03ED934/2003 to DL from the Secretariat for Research and Technology of the Greek Ministry of Development.

Author information

Authors and Affiliations

  1. Laboratory of Haematology and Blood Transfusion Unit, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece

    M Politou & A Gialeraki

  2. Haematology Research Laboratory, Biomedical Research Foundation, Academy of Athens, Athens, Greece

    C Zoi, I J Dahabreh, D Loukopoulos & K Zoi

  3. Department of Pathophysiology, Medical School, National University of Athens, Athens, Greece

    I J Dahabreh

  4. Second Department of Cardiology, Attikon Hospital, School of Medicine, University of Athens, Athens, Greece. E-mail: kzoi@bioacademy.gr,

    L Rallidis

Authors
  1. M Politou
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C Zoi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. I J Dahabreh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L Rallidis
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A Gialeraki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. D Loukopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. K Zoi
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Politou, M., Zoi, C., Dahabreh, I. et al. No evidence of frequent association of the JAK2 V617F mutation with acute myocardial infarction in young patients. Leukemia 23, 1008–1009 (2009). https://doi.org/10.1038/leu.2008.368

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/leu.2008.368

This article is cited by

Search

Advanced search

Quick links